UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
CNS drugs, ISSN 1172-7047, 2001, Volume 15, Issue 4, pp. 338 - 338
Journal Article
Annual review of medicine, ISSN 0066-4219, 1/2013, Volume 64, Issue 1, pp. 393 - 406
cognition | clozapine | extrapyramidal | antipsychotic | schizophrenia | psychosis | metabolic | Antipsychotic Agents - classification | Psychotic Disorders - physiopathology | Antipsychotic Agents - therapeutic use | Humans | Treatment Outcome | Psychotic Disorders - drug therapy | Cognition - drug effects | Physiological aspects | Antipsychotic drugs | Neural circuitry | Health aspects | Psychotropic drugs | Schizophrenia | Mental health care | Side effects | Psychopathology | Index Medicus
Journal Article
CNS drugs, ISSN 1172-7047, 8/1997, Volume 8, Issue 2, pp. 161 - 161
Journal Article
CNS & neurological disorders drug targets, ISSN 1871-5273, 10/2017, Volume 16, Issue 8, pp. 900 - 906
Psychosis | Atypical antipsychotics | Pharmacogenetics | Dopamine | GABA | Acetylcholine | Cognition | Glutamate | Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Schizophrenia - metabolism | Schizophrenia - genetics | Antipsychotic Agents - therapeutic use | Cognition Disorders - etiology | Humans | Neurotransmitter Agents - metabolism | Schizophrenia - complications | Disease Management | Schizophrenia - drug therapy
Journal Article
5.
The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia
Current pharmaceutical design, ISSN 1381-6128, 2014, Volume 20, Issue 31, pp. 5104 - 5114
NOR | 5-HT7 | 5-HT1A | Schizophrenia | Cognition | Lurasidone | Declarative memory | PCP | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Receptors, N-Methyl-D-Aspartate - drug effects | Cognition Disorders - chemically induced | Humans | Schizophrenia - complications | Acetylcholine - metabolism | Excitatory Amino Acid Agonists - pharmacology | Cognition Disorders - drug therapy | Schizophrenic Psychology | Serotonin Antagonists - pharmacology | Brain - drug effects | Brain - metabolism | Cognition Disorders - complications | Animals | Recognition (Psychology) - drug effects | Antipsychotic Agents - therapeutic use | GABA Agonists - pharmacology | Antipsychotic Agents - pharmacology | Schizophrenia - drug therapy | Dopamine - metabolism | Nicotinic Agonists - pharmacology | Disease Models, Animal
Journal Article
Clinical schizophrenia & related psychoses, ISSN 1935-1232, 10/2012, Volume 6, Issue 3, pp. 134 - 144
Myocarditis | Metabolic side effects | Agranulocytosis | Schizophrenia | Treatment resistant | Clozapine | Suicide | Myocarditis - chemically induced | Agranulocytosis - chemically induced | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Humans | Risk Factors | Metabolic Diseases - epidemiology | Metabolic Diseases - chemically induced | Schizophrenia - epidemiology | Agranulocytosis - epidemiology | Antipsychotic Agents - administration & dosage | Myocarditis - epidemiology | Schizophrenia - drug therapy | Clozapine - adverse effects
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 12/2013, Volume 123, Issue 12, pp. 4986 - 4991
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Serotonin - physiology | Serotonin 5-HT2 Receptor Agonists - therapeutic use | Obesity - drug therapy | Benzazepines - adverse effects | Humans | Receptors, Serotonin - drug effects | Serotonin 5-HT2 Receptor Agonists - adverse effects | Serotonin 5-HT2 Receptor Agonists - pharmacology | Parkinson Disease - drug therapy | Piperidines - pharmacology | Urea - analogs & derivatives | Diabetes Mellitus, Type 2 - therapy | Heart Valve Diseases - chemically induced | Molecular Structure | Serotonin 5-HT2 Receptor Antagonists - adverse effects | Benzazepines - pharmacology | Parkinson Disease - psychology | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Serotonin 5-HT2 Receptor Antagonists - therapeutic use | Urea - therapeutic use | Benzazepines - therapeutic use | Piperidines - therapeutic use | Piperidines - adverse effects | Urea - adverse effects | Schizophrenia - drug therapy | Diabetes Mellitus, Type 2 - drug therapy | Urea - pharmacology | Serotonin agonists | Obesity | Receptors | Parkinson's disease | Serotonin | Lorcaserin | Dosage and administration | Cellular signal transduction | Research | Properties | Drug therapy | Psychotropic drugs | Proteins | Heart | Lysergic acid diethylamide--LSD | Bias | Cloning | Technological change | Cardiovascular disease | Smooth muscle | Drug dosages | Index Medicus | Abridged Index Medicus | Review
Journal Article
Journal of clinical psychopharmacology, ISSN 0271-0749, 02/2013, Volume 33, Issue 1, pp. 11 - 17
rs16147 | association | clozapine | NPY | weight gain | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Psycholeptics: tranquillizer, neuroleptic | Psychology. Psychoanalysis. Psychiatry | Psychoses | Adult and adolescent clinical studies | Psychopharmacology | Pharmacology. Drug treatments | Psychopathology. Psychiatry | Schizophrenia | Biological and medical sciences | Medical sciences | Neuropharmacology | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Neuropeptide Y - genetics | Young Adult | Adult | Female | Weight Gain - drug effects | Ohio - epidemiology | European Continental Ancestry Group - genetics | Risk Assessment | Gene Frequency | Risk Factors | African Americans - genetics | Genotype | Chi-Square Distribution | Germany - epidemiology | Phenotype | Schizophrenia - ethnology | Receptor, Cannabinoid, CB1 - genetics | Analysis of Variance | Weight Gain - genetics | Benzodiazepines - adverse effects | Polymorphism, Single Nucleotide | Schizophrenia - drug therapy | Clozapine - adverse effects | New York - epidemiology | Index Medicus | Neuropeptide Y | Obesity | Neuroleptics | Mental disorders | Genetic diversity | Clozapine | Haloperidol | Body weight gain | Gene polymorphism | olanzapine | Side effects | Food intake | Cannabinoid receptors
Journal Article
9.
Full Text
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
2008, ISBN 0444532358, Volume 172
haloperidol | serotonin | microdialysis | clozapine | antipsychotic | schizophrenia | dopamine | Brain - anatomy & histology | Receptors, Dopamine - metabolism | Humans | Hallucinogens - metabolism | Serotonin Antagonists - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Neuroprotective Agents - metabolism | Receptors, Serotonin - metabolism | Brain - metabolism | Prolactin - metabolism | Animals | Protein Isoforms - metabolism | Antipsychotic Agents - therapeutic use | Neuronal Plasticity | Serotonin - metabolism | Antipsychotic Agents - metabolism | Serotonin Antagonists - metabolism | Schizophrenia - drug therapy | Dopamine - metabolism | Index Medicus
Book Chapter
Behavioural brain research, ISSN 0166-4328, 12/2008, Volume 195, Issue 1, pp. 98 - 102
Journal Article
11.
Full Text
Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory
The American journal of psychiatry, ISSN 0002-953X, 06/2015, Volume 172, Issue 6, pp. 502 - 504
Life Sciences & Biomedicine | Psychiatry | Science & Technology | Schizophrenia - blood | Humans | Psychotic Disorders - psychology | Female | Male | Memory, Short-Term - drug effects | Clozapine - analogs & derivatives | Psychotic Disorders - blood | Schizophrenia - drug therapy | Clozapine - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
Psychopharmacology, ISSN 0033-3158, 2/2011, Volume 213, Issue 2, pp. 289 - 305
Neurosciences | Dopamine | Serotonin | Schizophrenia | Cognition | Glutamate | Biomedicine | Phencyclidine | NMDA | 5-HT 2A | Novel object recognition | Pharmacology/Toxicology | Psychiatry | 5-HT 1A | 5-HT | Pharmacology & Pharmacy | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Schizophrenia - chemically induced | Cognition Disorders - physiopathology | Cognition Disorders - chemically induced | Humans | Excitatory Amino Acid Antagonists - toxicity | Receptors, Serotonin - drug effects | Motor Activity - drug effects | Rats | Cognition Disorders - drug therapy | Receptors, Serotonin - metabolism | Animals | Schizophrenia - physiopathology | Serotonin - metabolism | Antipsychotic Agents - pharmacology | Schizophrenia - drug therapy | Disease Models, Animal | Cognition & reasoning | Psychopharmacology | Index Medicus
Journal Article